You will get your price for BLTI today. The Question is do you want it?
08:59 ET Biolase Technology, Inc. sees prelim Q3 results below consensus; launches Waterlase MD product (BLTI) 8.49: Co announced preliminary Q3 results of revs between $11.5-12.1 mln, Reuters consensus is $15.8 mln. Co states, "We are disappointed in the level of sales for the quarter. Our initial analysis indicates that sales were adversely impacted by two factors. The first factor was rumors concerning the introduction of the new advanced Waterlase MD. We believe some potential buyers withheld their decision to purchase the Waterlase in anticipation of the Company's new product launch at the American Dental Association (A.D.A.) Annual Meeting in Orlando, FL. The second factor was the series of devastating hurricanes that struck the Gulf region resulting in the cancellation of the New Orleans Dental Conference 2004 as well as other scheduled sales activities. Historically, these events have been important vehicles for securing sales in the third quarter,". Co also lowers Q4 revs range to $17-20 mln (previously $23-25 mln), Reuters consensus is $24 mln, due to the disappointing A.D.A. attendance and product transition challenges as well as a possible lull in demand for capital equipment.
AI
